Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer-Reference-Cited by-同舟云学术

Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer

Published:2017-01-02 Issue:5 Volume:8 Page:8738-8751
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Inoue Yusuke¹²,Yoshimura Katsuhiro¹²,Kurabe Nobuya¹,Kahyo Tomoaki¹,Kawase Akikazu³,Tanahashi Masayuki⁴,Ogawa Hiroshi⁵,Inui Naoki²⁶,Funai Kazuhito³,Shinmura Kazuya¹,Niwa Hiroshi⁴,Suda Takafumi²,Sugimura Haruhiko¹

Affiliation:

1. Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan

2. Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan

3. First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan

4. Division of Thoracic Surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka, Japan

5. Department of Pathology, Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka, Japan

6. Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Landscape of adenosine pathway and immune checkpoint dual blockade in NSCLC: progress in basic research and clinical application;Frontiers in Immunology;2024-01-29

2. Novel targets for immune-checkpoint inhibition in cancer;Cancer Treatment Reviews;2023-11

3. Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC;JTO Clinical and Research Reports;2023-11

4. High Expression of Fas-Associated Factor 1 Indicates a Poor Prognosis in Non-Small-Cell Lung Cancer;Current Oncology;2023-10-25

5. Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer;Cancer Research and Treatment;2023-10-15